MAIA Biotechnology, Inc. (MAIA): R&D Expense

Annual figures by period end, from SEC filings.

$453.7K
Year ended 2025-12-31
-63.0%
3-year compound annual growth
$11.11M2021-12-31: $3.50M2022-12-31: $8.93M2023-12-31: $11.11M2024-12-31: $10.01M2025-12-31: $453.7K$453.7K
2021-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$453.7K-95.5%2026-03-23, From 2025-01-01
2024-12-31$10.01M-9.9%2025-03-21, From 2024-01-01
2023-12-31$11.11M+24.4%2025-03-21, From 2023-01-01
2022-12-31$8.93M+155.5%2024-03-21, From 2022-01-01
2021-12-31$3.50Mn/a2023-03-24, From 2021-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
MAIA Biotechnology, Inc. (MAIA)2025-12-31$453.7K-95.5%
Cocrystal Pharma, Inc. (COCP)2025-12-31$5.05M-59.7%
FibroBiologics, Inc. (FBLG)2025-12-31$7.41M+64.5%
Nanoviricides, Inc. (NNVC)2026-06-30$4.71M-15.2%
Can-Fite BioPharma Ltd. (CANF)2025-12-31$6.69M+16.3%
Kala Bio, Inc. (KALA)2025-12-31$18.78M-15.0%
Korsana Biosciences, Inc. (KRSA)2025-12-31$959.0K+235.3%
Medicus Pharma Ltd. (MDCX)2025-12-31$7.72M+118.9%
Oragenics Inc (OGEN)2025-12-31$2.39M-41.8%

Compare MAIA, COCP, FBLG, NNVC side by side · Screen every company in Pharmaceutical Preparations ↗